1. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370:319–328

2. McPartland JM, Duncan M, Di Marzo V, Pertwee RG (2015) Are cannabidiol and ∆9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol 172:737–753

3. Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 172:4790–4805

4. D’Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu Y-T, Braley G, Gueorguieva R, Krystal JH (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29:1558–1572

5. Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, Powell JF, Kapur S, Murray RM (2009) The acute effects of synthetic intravenous ∆9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 39:1607–1616

6. Broyd SJ, van Hell HH, Beale C, Yücel M, Solowij N (2016) Acute and chronic effects of cannabinoids on human cognition: a systematic review. Biol Psychiatry 79:557–567

7. Lorenzetti V, Solowij N, Yücel M (2016) The role of cannabinoids in neuroanatomic alterations in cannabis users. Biol Psychiatry 79:e17–e31

8. Yücel M, Lorenzetti V, Suo C, Zalesky A, Fornito A, Takagi MJ, Lubman DI, Solowij N (2016) Hippocampal harms, protection and recovery following regular cannabis use. Transl Psychiatry 6:e710

9. Di Forti M, Marconi A, Carra E et al (2015) Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case–control study. The Lancet Psychiatry 2:233–238

10. Bhattacharyya S, Morrison PD, Fusar-Poli P et al (2010) Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35:764–774

11. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkotter J, Hellmich M, Koethe D (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94

12. Osborne AL, Solowij N, Weston-Green K (2017) A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia. Neurosci Biobehav Rev 72:310–324

13. McGuire P, Robson P, Cubala WJ et al (2018) Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry 175:225–231

14. ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC (2016) Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol Psychiatry 79:613–619

15. Englund A, Freeman TP, Murray RM, McGuire P (2017) Can we make cannabis safer? The Lancet Psychiatry 4:643–648

16. Mechoulam R, Parker L (2013) Towards a better cannabis drug. Br J Pharmacol 170:1363–1364

17. Morgan CJA, Schafer G, Freeman TP, Curran HV (2010) Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry 197:285–290

18. Morgan CJA, Curran HV (2008) Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 192:306–307

19. Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MP (2011) Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 130:216–221

20. Englund A, Morrison PD, Nottage J et al (2013) Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 27:19–27

21. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76:245–250

22. Malone DT, Jongejan D, Taylor DA (2009) Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats. Pharmacol Biochem Behav 93:91–96

23. Murphy M, Mills S, Winstone J, Leishman E, Wager-Miller J, Bradshaw H, Mackie K (2017) Chronic adolescent ∆(9)-tetrahydrocannabinol treatment of male mice leads to long-term cognitive and behavioral dysfunction, which are prevented by concurrent cannabidiol treatment. Cannabis Cannabinoid Res 2:235–246

24. Beale C, Broyd SJ, Chye Y, Suo C, Schira M, Galettis P, Martin JH, Yücel M, Solowij N (2018) Prolonged cannabidiol treatment effects on hippocampal subfield volumes in current cannabis users. Cannabis Cannabinoid Res 3:94–107

25. Solowij N, Broyd SJ, Beale C, Prick J-A, Greenwood L-M, van Hell H, Suo C, Galettis P, Pai N, Fu S, Croft RJ, Martin JH, Yücel M (2018) Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial. Cannabis Cannabinoid Res 3:21–34

26. Karniol IG, Carlini EA (1973) Pharmacological interaction between cannabidiol and δ9-tetrahydrocannabinol. Psychopharmacologia 33:53–70

27. Zuardi AW, Teixeira NA, Karniol IC (1984) Pharmacological interaction of the effects of delta 9-trans-tetrahydrocannabinol and cannabidiol on serum corticosterone levels in rats. Arch Int Pharmacodyn Ther 269:12–19

28. Varvel SA, Wiley JL, Yang R, Bridgen DT, Long K, Lichtman AH, Martin BR (2006) Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology 186:226–234

29. Hayakawa K, Mishima K, Hazekawa M, Sano K, Irie K, Orito K, Egawa T, Kitamura Y, Uchida N, Nishimura R, Egashira N, Iwasaki K, Fujiwara M (2008) Cannabidiol potentiates pharmacological effects of ∆9-tetrahydrocannabinol via CB1 receptor-dependent mechanism. Brain Res 1188:157–164

30. Wright MJ Jr, Vandewater SA, Taffe MA (2013) Cannabidiol attenuates deficits of visuospatial associative memory induced by Delta(9) tetrahydrocannabinol. Br J Pharmacol 170:1365–1373

31. Klein C, Karanges E, Spiro A et al (2011) Cannabidiol potentiates ∆9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology 218:443–457

32. Todd SM, Arnold JC (2016) Neural correlates of interactions between cannabidiol and ∆(9) -tetrahydrocannabinol in mice: implications for medical cannabis. Br J Pharmacol 173:53–65

33. Todd SM, Zhou C, Clarke DJ, Chohan TW, Bahceci D, Arnold JC (2017) Interactions between cannabidiol and ∆9-THC following acute and repeated dosing: rebound hyperactivity, sensorimotor gating and epigenetic and neuroadaptive changes in the mesolimbic pathway. Eur Neuropsychopharmacol 27:132–145

34. Morgan CJ, Freeman TP, Schafer GL, Curran HV (2010) Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 35:1879–1885

35. Hindocha C, Freeman TP, Schafer G, Gardener C, Das RK, Morgan CJ, Curran HV (2015) Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol 25:325–334

36. Mechoulam R, Parker LA (2013) The endocannabinoid system and the brain. Annu Rev Psychol 64:21–47

37. Draycott B, Loureiro M, Ahmad T, Tan H, Zunder J, Laviolette SR (2014) Cannabinoid transmission in the prefrontal cortex bi-phasically controls emotional memory formation via functional interactions with the ventral tegmental area. J Neurosci 34:13096–13109

38. Loureiro M, Renard J, Zunder J, Laviolette SR (2015) Hippocampal cannabinoid transmission modulates dopamine neuron activity: impact on rewarding memory formation and social interaction. Neuropsychopharmacology 40:1436–1447

39. Guimarães FS, Chiaretti TM, Graeff FG, Zuardi AW (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology 100:558–559

40. Campos AC, Guimarães FS (2009) Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 33:1517–1521

41. Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, Hallak JEC, Guimarães FS, Crippa JAS (2017) Inverted U-shaped dose–response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol 8:259–259

42. Linares IM, Zuardi AW, Pereira LC, Queiroz RH, Mechoulam R, Guimarães FS, Crippa JA (2018) Cannabidiol presents an inverted U-shaped dose–response curve in a simulated public speaking test. Braz J Psychiatry. https://doi.org/10.1590/1516-4446-2017-0015

43. Watanabe K, Kayano Y, Matsunaga T, Yamamoto I, Yoshimura H (1996) Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. Biol Pharm Bull 19:1109–1111

44. Rakhshan F, Day TA, Blakely RD, Barker EL (2000) Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. J Pharmacol Exp Ther 292:960–967

45. Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta(9)-tetrahydrocannabinol, cannabidiol and Delta(9)-tetrahydrocannabivarin. Br J Pharmacol 153:199–215

46. Zuardi AW, Karniol IG (1983) Effects on variable-interval performance in rats of delta 9-tetrahydrocannabinol and cannabidiol, separately and in combination. Braz J Med Biol Res 16:141–146

47. Zuardi AW, Hallak JEC, Crippa JAS (2012) Interaction between cannabidiol (CBD) and Delta(9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids. Psychopharmacology 219:247–249

48. Arnold JC, Boucher AA, Karl T (2012) The Yin and Yang of cannabis-induced psychosis: the actions of ∆9-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia. Curr Pharm Des 18:5113–5130

49. Silveira MM, Arnold JC, Laviolette SR, Hillard CJ, Celorrio M, Aymerich MS, Adams WK (2017) Seeing through the smoke: human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks. Neurosci Biobehav Rev 76:380–395

50. Hložek T, Uttl L, Kadeřábek L, Balíková M, Lhotková E, Horsley RR, Nováková P, Šíchová K, Štefková K, Tylš F, Kuchař M, Páleníček T (2017) Pharmacokinetic and behavioural profile of THC, CBD, and THC + CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC. Eur Neuropsychopharmacol 27:1223–1237

51. Bornheim LM, Kim KY, Li J, Perotti BY, Benet LZ (1995) Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab Dispos 23:825–831

52. Jones G, Pertwee RG (1972) A metabolic interaction in vivo between cannabidiol and ∆1-tetrahydrocannabinol. Br J Pharmacol 45(2):375–377

53. Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42:327–360

54. Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R (2006) Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci 95:1308–1317

55. Solowij N (2018) Peering through the haze of smoked vs vaporized cannabis—to vape or not to vape? JAMA Netw Open 1:e184838

56. Spindle TR, Cone EJ, Schlienz NJ et al (2018) Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: a crossover trial. JAMA Netw Open 1:e184841

57. Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV (2018) Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry 8:181

58. Potter DJ, Clark P, Brown MB (2008) Potency of ∆9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 53:90–94

59. Swift W, Wong A, Li KM, Arnold JC, McGregor IS (2013) Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PLoS One 8:e70052

60. Solowij N, Broyd SJ, van Hell HH, Hazekamp A (2014) A protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆9-tetrahydrocannabinol (THC) by vaporisation. BMC Pharmacol Toxicol 15:58

61. Demirakca T, Sartorius A, Ende G, Meyer N, Welzel H, Skopp G, Mann K, Hermann D (2011) Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug Alcohol Depend 114:242–245

62. Sobell L, Sobell M (1992) Timeline follow-back: a technique for assessing self-reported ethanol consumption. In: Allen J, Litten RZ (eds) Measuring alcohol consumption: psychosocial and biological methods. Humana Press, Totowa, pp 41–72

63. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M (1993) Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction 88:791–804

64. Sheehan DV, Lecrubier Y, Sheehan KH et al (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22–33

65. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA (1983) Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press, Palo Alto

66. Beck AT, Ward C, Mendelson M (1961) Beck Depression Inventory (BDI). Arch Gen Psychiatry 4:561–571

67. Stefanis N, Hanssen M, Smirnis N, Avramopoulos D, Evdokimidis I, Stefanis C, Verdoux H, Van Os J (2002) Evidence that three dimensions of psychosis have a distribution in the general population. Psychol Med 32:347–358

68. Raine A (1991) The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr Bull 17:555

69. Gossop M, Darke S, Griffiths P, Hando J, Powis B, Hall W, Strang J (1995) The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 90:607–614

70. Barkus EJ, Stirling J, Hopkins RS, Lewis S (2006) Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology 39:175–178

71. Niesink RJ, Rigter S, Koeter MW, Brunt TM (2015) Potency trends of ∆9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in The Netherlands: 2005–15. Addiction 110:1941–1950

72. Galettis P (2016) Development of a simple LCMSMS method for THC and metabolites in plasma. Asia Pac J Clin Oncol 12:13–34

73. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM (1998) Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 11:125–136

74. Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP (1998) Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesia 88:82–88

75. Zuurman L, Roy C, Schoemaker RC et al (2008) Effect of intrapulmonary tetrahydrocannabinol administration in humans. J Psychopharmacol 22:707–716

76. Mason OJ, Morgan CJM, Stefanovic A, Curran HV (2008) The Psychotomimetic States Inventory (PSI): Measuring psychotic-type experiences from ketamine and cannabis. Schizophr Res 103:138–142

77. Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10:799–812

78. Russo E, Guy GW (2006) A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66:234–246

79. Hallak JEC, Dursun SM, Bosi DC et al (2011) The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Prog Neuropsychopharmacol Biol Psychiatry 35:198–202

80. Tham M, Yilmaz O, Alaverdashvili M, Kelly MEM, Denovan-Wright EM, Laprairie RB (2018) Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br J Pharmacol. https://doi.org/10.1111/bph.14440

81. Straiker A, Dvorakova M, Zimmowitch A, Mackie K (2018) Cannabidiol inhibits endocannabinoid signaling in autaptic hippocampal neurons. Mol Pharmacol 94:743–748

82. Kathmann M, Flau K, Redmer A, Tränkle C, Schlicker E (2006) Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol 372:354–361

83. Crippa JA, Guimarães FS, Campos AC, Zuardi AW (2018) Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age. Front Immunol 9:2009

84. Baillie GL, Horswill JG, Anavi-Goffer S et al (2013) CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity. Mol Pharmacol 83:322–338

85. Priestley RS, Nickolls SA, Alexander SPH, Kendall DA (2015) A potential role for cannabinoid receptors in the therapeutic action of fenofibrate. FASEB J 29:1446–1455

86. Taylor L, Gidal B, Blakey G, Tayo B, Morrison G (2018) A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs 32:1053–1067

87. Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB (1976) Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clin Pharmacol Ther 19:300–309

88. Fleming A (2018) Cannabis health products are everywhere—but do they live up to the hype? The Guardian. https://www.theguardian.com/lifeandstyle/2018/oct/15/cannabis-health-products-live-up-to-hype-cannabidiol-cbd. Accessed 15 Oct 2018